Skip to main content
. 2020 Feb 25;11(4):909–918. doi: 10.1002/jcsm.12559

Figure 3.

Figure 3

Summary of treatment effect of elamipretide on efficacy endpoints. Outcome measures used in the MMPOWER‐2 trial are highlighted in this forest plot. Analyses of functional tests and of patient‐reported as well as physician‐reported outcomes suggest potential with elamipretide in participants with primary mitochondrial myopathy.